BOSTON--(BUSINESS WIRE)--Beaconcure, Inc., a leader in AI-enabled clinical data validation and automation, announces that Christine Oliver has been appointed as Chief Executive Officer, effective May 6, 2024. She succeeds Yoran Bar, co-founder and CEO of the company. Mr. Bar has been appointed to the newly created position of Chief Innovation Officer and will continue to contribute to the successful development and deployment of the company’s core technologies.
Beaconcure was founded in 2016 by Mr. Bar with co-founder Ilan Carmeli, the company's Chief Operating Officer. Since then, Beaconcure has emerged as a global leader in developing innovative solutions for the Biometrics and Life Sciences industry. Under Mr. Bar's leadership, the company developed its core IP and technology and established key strategic partnerships with global, top 10 pharmaceutical companies and CROs. These partnerships have validated and expanded the use of Verify, Beaconcure’s platform for clinical study analysis validation and collaboration. Mr. Bar transitions from his role as CEO with Beaconcure well positioned in the market, after guiding the company through a Series B financing round in 2023 and initial commercial growth.
Rick Riegel, Chairman of the Beaconcure Board of Directors, says, “Speaking on behalf of the Board, we’d like to thank Yoran for his leadership and couldn’t be more excited about the state of Beaconcure and the opportunity moving forward. We extend a warm welcome to Christine, who has the leadership qualities, the track record, and the industry and operational expertise the company requires at this stage of its growth to capitalize on the increased demand for Beaconcure’s solutions. Her well-established reputation for delivering valuable technology solutions to the pharmaceutical industry and ensuring customer success is second to none.”
Before assuming her role at Beaconcure, Ms. Oliver held various positions spanning over a decade at endpoint Clinical, a pioneering firm in the clinical technology space. Most recently, she served as CEO, steering the company to achieve double-digit year-over-year growth in both revenue and profitability, ultimately leading to its sale to Arsenal Capital Partners in March 2024. Throughout her tenure, endpoint Clinical grew to serve hundreds of pharmaceutical customers and thousands of clinical trials, and played a vital role in the fight against the pandemic, collaborating on emergency use authorization vaccine development for COVID-19. Christine brings a wealth of experience to the company, having held senior positions on the biopharmaceutical sponsor side at Takeda, alongside roles at renowned Contract Research Organizations like Labcorp and Parexel.
"I'm truly honored to join Beaconcure during this exciting phase of expansion, propelled by the exceptional talent and unwavering dedication of our team. Beaconcure's technology meets a crucial industry need by advancing and automating the way we have been running statistical analysis for decades, enhancing both efficiency and accuracy. It is rare to find a proven solution in our industry that delivers a clear value proposition in such a short period of time for its customers. I look forward to leading this company and working closely with our growing client base," says Ms. Oliver.
About Beaconcure, Inc.
Beaconcure supports biopharmaceutical companies and CROs with Verify, a secure online workspace for AI-enabled clinical study analysis validation. Designed in partnership with trusted large pharmaceutical companies and used in an increasing number of approved products, Verify streamlines validation workflows, reduces error rates, and increases efficiency compared to traditional processes. For more information, visit www.beaconcure.com.
